Pathogenesis and treatment of ANCA-associated vasculitides

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages 11-14

  Kallenberg, Cees G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ANCA associated vasculitis; MPO ANCA; Pathogenesis; PR3 ANCA; Treatment

Indexed keywords

AZATHIOPRINE; COMPLEMENT COMPONENT C5A RECEPTOR; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLATE MOFETIL; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT;

ANCA ASSOCIATED VASCULITIS; ARTICLE; CELLULAR IMMUNITY; HUMAN; IMMUNE RESPONSE; LEUKOCYTE ACTIVATION; NONHUMAN; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; ANIMAL; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; B LYMPHOCYTE; COMPLEMENT ALTERNATIVE PATHWAY; DRUG EFFECTS; IMMUNOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; B-LYMPHOCYTES; COMPLEMENT PATHWAY, ALTERNATIVE; CYCLOPHOSPHAMIDE; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; REMISSION INDUCTION; RISK FACTORS; RITUXIMAB; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84953343675     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. JENNETTE JC, FALK RJ, BACON PA et al.: 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 2013; 65: 1-11.
2. KALLENBERG CG: Churg-Strauss syndrome: just one disease entity? Arthritis Rheum 2005; 52: 2589-93.
3. KALLENBERG CG: Key advances in the clinical approach to ANCA-associated vasculitis. Nat Rev Rheumatol 2014; 10: 484-93.
4. TOMASSON G, GRAYSON PC, MAHR AD et al.: Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis-a meta-analysis. Rheumatology 2012; 51: 100-9.
5. ROTH AJ, OOI JD, HESS JJ et al.: Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest 2013; 123: 1773-83.
6. ESPY C, MORELLE W, KAVIAN N et al.: Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's). Arthritis Rheum 2011; 63: 2105-15.
7. BANSAL PJ, TOBIN MC: Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 2004; 93: 398-401.
8. LYONS PA, RAYNER TF, TRIVEDI S et al.: Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012; 367: 214-23.
9. SCHREIBER A, KETTRITZ R: The neutrophil in antineutrophil cytoplasmic autoantibody-associated vasculitis. J Leukoc Biol 2013; 94: 623-31.
10. JENETTE JC, XIAO H, HU P et al.: Complement in ANCA-associated vasculitis. Semin Nephrol 2013; 33: 557-64.
11. SALAMA AD, LITTLE MA: Animal models of antineutrophil cytoplasm antibody-associated vasculitis. Curr Opin Rheumatol 2012; 24: 1-7.
12. LITTLE MA, Al-ANI B, REN S et al.: Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system.PLoS One 2012; 7: e28626.
13. ABDULAHAD WH, LAMPRECHT P, KALLENBERG CG: T-helper cells as new players in ANCA-associated vasculitides. Arthritis Res Ther 2011; 13: 236.
14. KALLENBERG CG, STEGEMAN CA, ABDULAHAD WH, HEERINGA P: Pathogenesis of ANCA-associated vasculitis: new possibilities for intervention. Am J Kidney Dis 2013; 62: 1176-87.
15. LEPSE N, ABDULAHAD WH, KALLENBERG CG, HEERINGA P: Immune regulatory mechanisms in ANCA-associated vasculitides. Autoimmun Rev 2011; 11: 77-83.
16. MUKHTYAR C, GUILLEVIN L, CID MC et al.: EULAR recommendations for the management of small and medium vessel vasculitis. Ann Rheum Dis 2009; 68: 310-7.
17. SCHONERMARCK U, GROSS WL, de GROOT K: Treatment of ANCA-associated vasculitis. Nat Rev Nephrol 2014; 10: 25-36.
18. STONE JH, MERKEL PA, SPIERA R et al.: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-32.
19. SPECKS U, MERKEL PA, SEO P et al.: Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013; 369: 417-27.
20. JONES RB, TERVAERT JW, HAUSER T et al.: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211-20.
21. GUILLEVIN L, PAGNOUX C, KARRAS A et al.: Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014; 371: 1771-80.
22. XIAO H, DAIRAGHI DJ, POWERS JP et al.: C5a receptor (CD88) blockade protects against MP0-ANCA GN. J Am Soc Nephrol 2014; 25: 225-31.